FDA slows down on drug reviews, approvals amid Trump admin chaos
The article discusses the impact of the Trump administration's chaos on the U.S. Food and Drug Administration (FDA) and its drug review and approval processes. It reports that the FDA has slowed down its drug reviews and approvals due to the ongoing government shutdown. The shutdown has also resulted in the agency not accepting any new drug submissions. This situation has raised concerns about the potential delay in the availability of new treatments for patients. The article suggests that the turmoil in the Trump administration has contributed to the disruption in the FDA's operations, which could have significant implications for the pharmaceutical industry and the healthcare system as a whole. The article emphasizes the need for a stable and functional FDA to ensure the timely approval of safe and effective drugs for the benefit of the public.
Source: For the complete article, please visit the original source link below.
